Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Finished Goods (2020 - 2022)

Rapid Micro Biosystems' Finished Goods history spans 3 years, with the latest figure at $8.0 million for Q2 2022.

  • On a quarterly basis, Finished Goods rose 165.47% to $8.0 million in Q2 2022 year-over-year; TTM through Jun 2022 was $8.0 million, a 165.47% increase, with the full-year FY2021 number at $4.3 million, up 321.25% from a year prior.
  • Finished Goods hit $8.0 million in Q2 2022 for Rapid Micro Biosystems, up from $5.9 million in the prior quarter.
  • Over the last five years, Finished Goods for RPID hit a ceiling of $8.0 million in Q2 2022 and a floor of $1.0 million in Q4 2020.
  • Historically, Finished Goods has averaged $4.2 million across 3 years, with a median of $3.7 million in 2021.
  • Biggest five-year swings in Finished Goods: surged 321.25% in 2021 and later surged 165.47% in 2022.
  • Tracing RPID's Finished Goods over 3 years: stood at $1.0 million in 2020, then surged by 321.25% to $4.3 million in 2021, then soared by 86.28% to $8.0 million in 2022.
  • Business Quant data shows Finished Goods for RPID at $8.0 million in Q2 2022, $5.9 million in Q1 2022, and $4.3 million in Q4 2021.